Truvada

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

HIV/AIDS

Conditions

HIV/AIDS, Substance Use Disorders, Adherence, Medication

Trial Timeline

Oct 1, 2018 → Apr 22, 2020

NCT ID

NCT03842436

About Truvada

Truvada is a approved stage product being developed by Gilead Sciences for HIV/AIDS. The current trial status is completed. This product is registered under clinical trial identifier NCT03842436. Target conditions include HIV/AIDS, Substance Use Disorders, Adherence, Medication.

What happened to similar drugs?

2 of 4 similar drugs in HIV/AIDS were approved

Approved (2) Terminated (1) Active (2)

✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved

✅Emtricitabine and TenofovirGilead SciencesApproved

🔄Biktarvy + SymtuzaGilead SciencesPhase 3

🔄TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06631365	Phase 2	Recruiting	Oct 2, 2023	Apr 1, 2025	HIV-1-infection
NCT03512418	Phase 3	Completed	Jun 20, 2019	Apr 10, 2024	HIV Infections
NCT03842436	Approved	Completed	Oct 1, 2018	Apr 22, 2020	HIV/AIDS
NCT02732730	Approved	Completed	Oct 12, 2016	Oct 25, 2018	HIV
NCT00323687	Approved	Completed	Sep 1, 2004	Jan 1, 2007	HIV-1 Infection

Competing Products

11 competing products in HIV/AIDS

See all competitors

Product	Company	Stage	Hype Score
Metformin	Merck	Phase 2/3	34
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC	Gilead Sciences	Pre-clinical	18
Switch to E/C/FTC/TAF daily	Gilead Sciences	Phase 1/2	32
Biktarvy + Symtuza	Gilead Sciences	Phase 3	40
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)	Gilead Sciences	Approved	35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet	Gilead Sciences	Phase 2	35
Emtricitabine and Tenofovir	Gilead Sciences	Approved	39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets	Gilead Sciences	Phase 3	47
Maraviroc	Pfizer	Phase 1	29
Efavirenz	Bristol Myers Squibb	Pre-clinical	26
Moxifloxacin + Placebo + Efavirenz	Bristol Myers Squibb	Phase 1	29